As healthcare costs continue to rise, pharmacy leaders are turning to manufacturers who can deliver affordable medications without compromising quality. Amneal Pharmaceuticals is at the
Patented Lyobag technology offers enhanced administration safety, efficiency, and stability. BRIDGEWATER, N.J., September 2, 2025 – Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal or the “Company”)
PRACTICE SETTINGS: LONG-TERM CARE PHARMACY RESOURCES A long-term care pharmacy is a specialized pharmacy service designed to meet the unique medication and pharmaceutical needs of
McKesson ideaShareJuly 10 -13, 2025 | Nashville, TN McKesson ideaShare is the nation’s leading event for community pharmacy, designed to empower both current and future
MANUFACTURING: GENERICS, BRAND NAME, BIOTECH A branded pharmaceutical manufacturer is a company that develops, produces, and markets pharmaceutical products under a proprietary brand name. These
Cardinal Health RBC July 9-12, 2025 | Denver, CO The Cardinal Health Retail Business Conference (RBC) is an annual conference recognizing independent pharmacies and their
May 27, 2025 BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched Exenatide 1.2 mL and 2.4 mL prefilled pen injection, an AP-rated generic equivalent for BYETTA.
– First ready-to-use, subcutaneous formulation of Bortezomib now available – Marks Amneal’s fourth 505(b)(2) injectable product launch in the last year BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal
– Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD® – Lenalidomide capsules, referencing REVLIMID® BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the
January 23, 2025 Approval of three important therapies for dementia, oncology and gastrointestinal disease Granted 180-day exclusivity for memantine/donepezil extended-release capsules Tentative approval of rifaximin,
